Cite
HARVARD Citation
Powles, T. et al. (2021). Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet oncology. 22 (7), pp. 931-945. [Online].